Robert Giugliano, MD, SM, on the Effects of Ezetimibe Add-on Therapy Among Older Adults

In this podcast, Robert Giugliano, MD, SM, discusses his latest analysis of IMPROVE-IT data, which compared simvastatin-ezetimibe combination therapy with simvastatin monotherapy among patients aged 75 years or older who had had acute coronary syndrome. He also explains which patient groups benefitted the most from ezetimibe add-on therapy.

Robert P. Giugliano, MD, SM, is senior investigator at the TIMI Study Group at the Brigham and Women’s Hospital, staff physician in the Cardiovascular Division at Harvard Medical School, and associate professor of medicine at Harvard Medical School in Boston, Massachusetts. 

Additional Resources:

• Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older. JAMA Cardiol. 2019;4(9):846-854. https://doi.org/10.1001/jamacardio.2019.2306. 
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/cir.0000000000000625. 
• Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) [published online August 2019]. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz455.